Get the Stockscreener App
80.29
1.13%
-1.3747
Inhibrx Biosciences Inc stock is traded at $80.29, with a volume of 60,360.
It is down -1.13% in the last 24 hours and up +126.47% over the past month.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
See More
Previous Close:
$81.66
Open:
$80.25
24h Volume:
60,360
Relative Volume:
0.21
Market Cap:
$1.16B
Revenue:
$1.80M
Net Income/Loss:
$1.76B
P/E Ratio:
0.6765
EPS:
118.674
Net Cash Flow:
$-149.23M
1W Performance:
+37.19%
1M Performance:
+126.47%
6M Performance:
+564.49%
1Y Performance:
+410.98%
1-Day Range:
$77.58
$81.07
1-Week Range:
$57.83
$83.95
52-Week Range:
$10.80
$83.95
Inhibrx Biosciences Inc Stock (INBX) Company Profile
Name
Inhibrx Biosciences Inc
Sector
Industry
Phone
(858) 795-4220
Address
11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA
Compare INBX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INBX
Inhibrx Biosciences Inc
|
80.17 | 1.18B | 1.80M | 1.76B | -149.23M | 118.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
423.38 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
636.02 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.39 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
824.56 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
181.97 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Inhibrx Biosciences Inc Stock (INBX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-23-24 | Initiated | JMP Securities | Mkt Perform |
| Jan-23-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Mar-16-22 | Initiated | SMBC Nikko | Outperform |
| Sep-21-21 | Initiated | JMP Securities | Mkt Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Sep-14-20 | Initiated | Credit Suisse | Outperform |
| Sep-14-20 | Initiated | Evercore ISI | Outperform |
View All
Inhibrx Biosciences Inc Stock (INBX) Latest News
Tick level data insight on Inhibrx Biosciences Inc. volatilityJuly 2025 Reactions & Daily Profit Focused Stock Screening - newser.com
Regression analysis insights on Inhibrx Biosciences Inc. performanceQuarterly Profit Report & Technical Entry and Exit Tips - newser.com
What Wall Street predicts for Inhibrx Biosciences Inc. stock price2025 Big Picture & Technical Buy Zone Confirmations - newser.com
Is Inhibrx Biosciences Inc. stock resilient to inflationEntry Point & Stepwise Trade Signal Implementation - newser.com
Inhibrx Biosciences Inc. stock daily chart insightsJobs Report & Free AI Powered Buy and Sell Recommendations - newser.com
Why Inhibrx Biosciences Inc. stock appeals to analysts2025 Sector Review & Consistent Profit Trading Strategies - newser.com
Will Inhibrx Biosciences Inc. stock benefit from sector rotation2025 EndofYear Setup & Accurate Entry and Exit Point Alerts - newser.com
Ethic Inc. Purchases New Shares in Inhibrx Biosciences, Inc. $INBX - MarketBeat
Inhibrx Biosciences stock hits all-time high of 83.93 USD By Investing.com - Investing.com Australia
Inhibrx Biosciences stock hits all-time high of 83.93 USD - Investing.com
What does recent volatility data suggest for Inhibrx Biosciences Inc.Quarterly Risk Review & AI Optimized Trading Strategy Guides - newser.com
Biotech Stocks Hit 52-Week Highs: MTSR, INSM, ABVX, MAZE Lead October 30 Surge - RTTNews
How to recover losses in Inhibrx Biosciences Inc. stock2025 Short Interest & Community Verified Trade Signals - newser.com
Inhibrx Biosciences (NASDAQ:INBX) Trading Up 7.8%What's Next? - MarketBeat
Published on: 2025-10-30 05:00:27 - newser.com
Published on: 2025-10-30 02:27:04 - newser.com
Inhibrx Biosciences (NASDAQ:INBX) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Inhibrx Biosciences (NASDAQ:INBX) Hits New 12-Month HighHere's What Happened - MarketBeat
How hedge fund analytics apply to Inhibrx Biosciences Inc. stockTrade Volume Summary & Low Drawdown Momentum Ideas - newser.com
Published on: 2025-10-28 03:10:26 - newser.com
How Inhibrx Biosciences Inc. stock valuations compare to rivalsMarket Movement Recap & Daily Entry Point Trade Alerts - Fundação Cultural do Pará
Is Inhibrx Biosciences Inc. stock supported by innovation pipelineJuly 2025 Selloffs & Entry Point Confirmation Signals - fcp.pa.gov.br
Is Inhibrx Biosciences Inc. stock recession proof2025 Trade Ideas & Free Community Consensus Stock Picks - Fundação Cultural do Pará
Inhibrx Biosciences: Cruising Toward FDA Approval, But Getting Ahead Of Itself - Seeking Alpha
Multi factor analysis applied to Inhibrx Biosciences Inc.Price Action & Real-Time Volume Trigger Notifications - newser.com
What high frequency data says about Inhibrx Biosciences Inc.Earnings Overview Summary & Low Volatility Stock Suggestions - newser.com
US Stocks Jump To Records Amid Weak Inflation: Investor Fear Eases, Greed Index Remains In 'Fear' Zone - NewsBreak: Local News & Alerts
Inhibrx Preps US Filing For Ozekibart In Rare Bone Cancer After Phase II Win - Citeline News & Insights
Inhibrx Biosciences Inc Stock (INBX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.21%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):